Here, expert scientists from industry and academia share their knowledge on the assembly of functional human tissues in vitro and how to design drug screenings predictive of human exposure. In so doing, they combine the latest technological developments with strategic outlooks, such as novel cell and tissue systems for drug screening and testing, as well as emerging in vitro culture technologies. Equally importantly, the book does not shy away from regulatory acceptance and ethical issues.
Here, expert scientists from industry and academia share their knowledge on the assembly of functional human tissues in vitro and how to design drug screenings predictive of human exposure. In so doing, they combine the latest technological developments with strategic outlooks, such as novel cell and tissue systems for drug screening and testing, as well as emerging in vitro culture technologies. Equally importantly, the book does not shy away from regulatory acceptance and ethical issues.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Dr. Uwe Marx After finishing medical training Uwe Marx received his doctorate degree in immunology from the Humboldt University, Berlin. In 1995 Dr. Marx was appointed Head of the Department of Medical Biotechnology at Leipzig University and joined ProBioGen, Berlin, in 2000 as Chief Scientific Officer. With more than 20 years of experience in protein drug development and improvement of cell culture techniques, Uwe Marx has published more than 50 scientific papers and holds numerous patents.
Dr. Volker Sandig Volker Sandig studied medicine and received his PhD in molecular biology from the Humboldt University, Berlin. He designed experimental strategies for adenovirus based tumor treatment and directed research projects in cell cycle regulation and artificial promoters at the Max Planck Society and Hepavec, a former Berlin-based biotech company. He then joined Merck Research Laboratories, USA and was appointed Vice President Molecular Biology and Virology at ProBioGen, Berlin, Germany in 2000.
Inhaltsangabe
Foreword (Rolf Krebs) Preface List of Contributors PART I EMERGING IN-VITRO CULTURE TECHNOLOGIES Intelligent Biomatrices and Engineered Tissue Constructs: In-Vitro Models for Drug Discovery and Toxicity Testing (Philip Lazarovici, Mengyan Li, Anat Perets, Mark J. Mondrinos, Shimon Lecht, Christopher D. Koharski, Paul R. Bidez III, Christine M. Finck, and Peter I. Lelkes) An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture (Ralf Pörtner and Christoph Giese) An Overview on Bioelectronic and Biosensoric Microstructures Supporting High-Content Screening in Cell Cultures (Andrea A. Robitzki and Andrée Rothermel) Novel In-Vitro Exposure Techniques for Toxicity Testing and Biomonitoring of Airborne Contaminants (Amanda Hayes, Shahnaz Bakand, and Chris Winder) PART II PRIMARY TISSUES AND CELL LINES IN DRUG SCREENING/TESTING Drug Screening Using Cell Lines: Cell Supply, High-Throughput and High-Content Assays (Christa Burger, Oliver Pöschke, and Mirek R. Jurzak) Cell Lines and Primary Tissues for In-Vitro Evaluation of Vaccine Efficacy (Anthony Meager) Designer Cells Derived from Primary Tissue and Designed Cell Lines as a Sustainable Cell Source for Drug Discovery and Safety Assessment (Volker Sandig and Ingo Jordan) How Human Embryonic Stem Cell Research Can Impact In-Vitro Drug Screening Technologies of the Future (André Schrattenholz and Martina Klemm) PART III THE USE OF HUMAN TISSUES IN DRUG DISCOVERY: SCIENTIFIC, ETHICAL, LEGAL, AND REGULATORY ENVIRONMENTS Availability, Standardization and Safety of Human Cells and Tissues for Drug Screening and Testing (Glyn N. Stacey and Thomas Hartung) Ethical Environment and Scientific Rationale Towards In-Vitro Alternatives to Animal Testing: Where Are We Going? (Horst Spielmann) PART IV SUMMARY AND VISIONS How Drug Development of the 21st Century Could Benefit from Human Micro-Organoid In-Vitro Technologies (Uwe Marx) Subject Index
Foreword (Rolf Krebs) Preface List of Contributors PART I EMERGING IN-VITRO CULTURE TECHNOLOGIES Intelligent Biomatrices and Engineered Tissue Constructs: In-Vitro Models for Drug Discovery and Toxicity Testing (Philip Lazarovici, Mengyan Li, Anat Perets, Mark J. Mondrinos, Shimon Lecht, Christopher D. Koharski, Paul R. Bidez III, Christine M. Finck, and Peter I. Lelkes) An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture (Ralf Pörtner and Christoph Giese) An Overview on Bioelectronic and Biosensoric Microstructures Supporting High-Content Screening in Cell Cultures (Andrea A. Robitzki and Andrée Rothermel) Novel In-Vitro Exposure Techniques for Toxicity Testing and Biomonitoring of Airborne Contaminants (Amanda Hayes, Shahnaz Bakand, and Chris Winder) PART II PRIMARY TISSUES AND CELL LINES IN DRUG SCREENING/TESTING Drug Screening Using Cell Lines: Cell Supply, High-Throughput and High-Content Assays (Christa Burger, Oliver Pöschke, and Mirek R. Jurzak) Cell Lines and Primary Tissues for In-Vitro Evaluation of Vaccine Efficacy (Anthony Meager) Designer Cells Derived from Primary Tissue and Designed Cell Lines as a Sustainable Cell Source for Drug Discovery and Safety Assessment (Volker Sandig and Ingo Jordan) How Human Embryonic Stem Cell Research Can Impact In-Vitro Drug Screening Technologies of the Future (André Schrattenholz and Martina Klemm) PART III THE USE OF HUMAN TISSUES IN DRUG DISCOVERY: SCIENTIFIC, ETHICAL, LEGAL, AND REGULATORY ENVIRONMENTS Availability, Standardization and Safety of Human Cells and Tissues for Drug Screening and Testing (Glyn N. Stacey and Thomas Hartung) Ethical Environment and Scientific Rationale Towards In-Vitro Alternatives to Animal Testing: Where Are We Going? (Horst Spielmann) PART IV SUMMARY AND VISIONS How Drug Development of the 21st Century Could Benefit from Human Micro-Organoid In-Vitro Technologies (Uwe Marx) Subject Index
Rezensionen
"...highly topical handbood..." -- Anticancer Research
"...Ohne Zweifel muss man das Buch als eine gelungene Zusammenstellung eines sehr wichtigen Gebietes in der modernen Wirktstoffforschung bewerten...Es steht daher außer Zweifel, dass das Buch seine Leserschaft finden wird." -- Pharmazie in unserer Zeit, 06/2007
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
